液体活检新进展
液体活检通过约10 mL血液或尿液检测肿瘤释放的细胞及细胞来源代谢物、蛋白、核酸和囊泡,作为微创全身肿瘤评估工具。其无细胞DNA和循环肿瘤DNA最常检测,在癌症筛查、治疗后残留病灶评估及预后预测方面显示前景;早期肿瘤阶段敏感性低于影像但特异性更高,可能比RECIST更早检测治疗反应。本文面向放射科医生综述近期进展、关键临床试验、美国监管批准及临床实施挑战。
要点
- 液体活检仅需约10 mL血液或尿液,可微创进行全身肿瘤评估。
- 早期肿瘤阶段液体活检敏感性低于影像,但特异性更高。
- 液体活检可能比RECIST更早检测治疗反应。
核心结论
- 液体活检是微创全身肿瘤评估工具,在癌症筛查、残留病灶评估和预后预测方面显示前景。
- 早期肿瘤阶段液体活检敏感性低于影像,但特异性更高,可能比RECIST更早检测治疗反应。
研究设计与样本
- 本文为综述,主要面向放射科医生,总结液体活检近期进展、关键临床试验结果和美国监管批准。
- 重点涉及淋巴瘤、乳腺癌、前列腺癌和黑色素瘤四种恶性肿瘤。
- 液体活检主要检测无细胞DNA和循环肿瘤DNA,仅需约10 mL血液或尿液。
诊断标准与关键数值
- 液体活检在早期肿瘤阶段敏感性低于影像,但特异性高于影像。
- 液体活检可能比RECIST更早检测治疗反应。
临床应用与阅片要点
- 液体活检可作为侵入性组织活检的替代选择,尤其适用于治疗反应评估和癌症治疗中突变监测等连续评估。
局限性
- 本文讨论了液体活检临床实施中当前的挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Liquid biopsy helps detect cells and cell-derived metabolites, proteins, nucleic acids, and vesicles that are shed into body fluids by tumors. This diagnostic test requires only approximately 10 mL of blood or urine. It has received considerable attention as a minimally invasive tool for whole-body tumor interrogation for use in patients with cancer. It poses an attractive and potentially cost-effective alternative to invasive tissue sampling through tissue biopsies, especially serial assessments, such as for treatment response evaluation and mutations that occur during cancer treatment. Cell-free and circulating tumor DNA are the most frequently tested liquid biopsy analytes, and have shown promise for cancer screening, assessment of residual disease after treatment, and clinical outcome prediction and prognostication. Whereas liquid biopsy is less sensitive than imaging in early tumor stages, it is more specific and may help detect treatment response earlier than the Response Evaluation Criteria in Solid Tumors, or RECIST. Aimed primarily at radiologists, this review article provides an update on recent developments in the use of liquid biopsy, including findings from landmark clinical trials and U.S. regulatory approvals as companion diagnostic tests for clinical use, particularly in four malignancies: lymphoma, breast cancer, prostate cancer, and melanoma. Finally, current challenges for the clinical implementation of liquid biopsy are discussed.
引用
- Mayerhoefer ME, Kienzle A, Woo S, et al. Update on Liquid Biopsy. Radiology. 2025. PMID: 40525978. doi:10.1148/radiol.241030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。